Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation ... https://t.co/5v5RzpTHo7
— Marisa Peer (@PeerMarisa) August 24, 2018
from Twitter https://twitter.com/PeerMarisa
August 24, 2018 at 12:40PM
No comments:
Post a Comment